Clinical trials: Elevated Risk of Cardiovascular Disease
Cardiomyopathy, Dilated, 3B
CRT-P or CRT-D in Dilated Cardiomyopathy
The ICD-Reality study is a non-commercial, investigator-led, multicenter, prospective, randomized, controlled trial. We aim to determine the effect of CRT-D or CRT-P implantation in non-ischemic cardiomyopathy and heart failure…
- Trial name
- CRT-REALITY (NCT04139460)
- Testing
- CRT-D, CRT-P
- Where
- Czechia
- Volunteers
- 924 people
- Sponsor
- University Hospital Olomouc
Medical Conditions to be Studied, Dyslipidemia
Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States
This is a multicenter observational cohort study with both retrospective and prospective data collection components in subjects with ASCVD.
- Conditions
- Medical Conditions to be Studied, Dyslipidemia, ASCVD Management
- Trial name
- NCT02993120
- Where
- 118 sites in United States
- Volunteers
- 5,006 people
- Sponsor
- Amgen
High-risk Percutaneous Coronary Intervention, Heart Disease, Coronary
VITALYST Early Feasibility Study in High-Risk PCI Patients (VITALYST EFS)
The VITALYST Early Feasibility study (EFS) is designed to evaluate the feasibility and safety of the VITALYST System in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).
- Trial name
- VITALYST EFS (NCT06132568)
- Testing
- VITALYST System
- Where
- 5 sites in United States, Sweden
- Volunteers
- 15 people
- Sponsor
- Boston Scientific Corporation
Carotid Artery Disease, Carotid Stenosis
Adapt Monorail Carotid Stent System: A Postmarket Clinical Follow-up Study
The purpose of this study is to get outcomes data for the Adapt Monorail Carotid System used in conjunction with the FilterWire Embolic protection system for treatment of patients that suffer from carotid artery stenosis and that…
- Conditions
- Carotid Artery Disease, Carotid Stenosis, Stroke
- Trial name
- ASTI (NCT01133327)
- Testing
- Carotid Artery Stenting
- Where
- 11 sites in Belgium, Germany and 1 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Multiple Myeloma, Newly Diagnosed
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of autologous stem cell transplantation combined with BCMA CAR-T therapy followed by GPRC5D/CD3 bispecific antibody maintenance in…
- Trial name
- CAREMM-005 (NCT07106710)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, BCMA CAR-T, GPRC5D/CD3 BiTEs
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Diabetic Retinopathy, Diabetic Macular Edema
Anti-VEGF Treatment for Prevention of PDR/DME
Multiple studies have implicated vascular endothelial growth factor VEGF as a major causative factor in human eye diseases characterized by neovascularization including proliferative diabetic retinopathy (PDR) and vascular…
- Trial name
- NCT02634333
- Testing
- Prompt aflibercept, Deferred laser, Deferred aflibercept
- Where
- 85 sites in United States, Canada
- Volunteers
- 399 people
- Sponsor
- Jaeb Center for Health Research
Cardiovascular Diseases
Identifying High- and Low-Risk Heart Failure Patients in the Emergency Department (The Stratify Study)
People with heart failure (HF) symptoms who are seen in the emergency department (ED) are often admitted to the hospital even though it may not be necessary.
- Trial name
- Stratify (NCT00508638)
- Where
- United States
- Volunteers
- 1,033 people
- Sponsor
- Vanderbilt University
Blood Loss, Surgical, Coagulation Disorder
Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
The goal of this clinical trial is to learn if reltodecacog alfa (VMX-C001) works to to allow blood clotting control in participants who take FXa Direct Oral Anticoagulants (DOACs) during surgery or other invasive procedures that…
- Trial name
- EQUILIBRIX-S (NCT07288489)
- Testing
- Reltodecacog alfa, Usual Pharmacological Care
- Where
- 77 sites in United States, Australia and 16 more
- Volunteers
- 800 people
- Sponsor
- VarmX B.V.
Polycythemia Vera, Essential Thrombocythemia
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Philadelphia-negative myeloproliferative neoplasms (MPN) are frequent and chronic myeloid malignancies including Polycythemia Vera (PV), essential thrombocythemia (ET), Primary Myelofibrosis (PMF) and Prefibrotic myelofibrosis…
- Conditions
- Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis, JAK2 V617F
- Trial name
- AVAJAK (NCT05198960)
- Testing
- Direct Oral Anticoagulants, Low-dose aspirin
- Where
- 42 sites in France
- Volunteers
- 1,308 people
- Sponsor
- University Hospital, Brest
Health Behavior
Evaluating the Impact of SomaSignal Tests on Medical Management and Change in Risk in Patients at Higher Risk of Cardiovascular Disease: A Feasibility and an Adaptive Implementation Study
Feasibility Study Informed consent will be obtained using an IRB-approved form. The first 12 consenting patients will be placed in the planned assessment group for feasibility and will not be randomized.
- Trial name
- SomaSignal (NCT04836117)
- Testing
- SomaSignal Test Results
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Intermountain Health Care, Inc.
Coronary Heart Disease
A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease
The purpose of this study is to evaluate the safety and cholesterol lowering effects of MPSK3169A when given as subcutaneous (SC) injections over a 24-week period to patients with a high risk of cardiovascular events and LDL-c…
- Trial name
- NCT01609140
- Testing
- MPSK3169A
- Where
- 73 sites in United States, Canada and 7 more
- Volunteers
- 248 people
- Sponsor
- Genentech, Inc.
Paroxysmal Atrial Fibrillation
Oral Anticoagulation Therapy Pilot Study
The objective of this study is to determine the safety of discontinuing oral anticoagulation therapy in high risk patients who have had a successful cardiac ablation and remain AF recurrence free for 3 months post ablation.
- Trial name
- OAT (NCT01959425)
- Testing
- Off OAT Group (Test), On OAT Group (Control)
- Volunteers
- 80 people
- Sponsor
- Biosense Webster, Inc.
Aerobic Exercise, Cardiorespiratory Fitness
Effects of Exergame in Patients at High Cardiovascular Risk.
Background: Exergaming is thought to have a similar effect on cardiovascular (CV) responses as aerobic fitness activities. The aim of this study was to compare the cardiovascular effects of exergaming and traditional treadmill…
- Conditions
- Aerobic Exercise, Cardiorespiratory Fitness, Cardiovascular Diseases
- Trial name
- NCT04042896
- Testing
- exergame, treadmill exercise
- Where
- South Korea
- Volunteers
- 64 people
- Sponsor
- Kyoung Im Cho
Hypertension, Cardiovascular Diseases
OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study
The purpose of this study is to investigate whether high-dose angiotensin II receptor blocker (ARB) monotherapy or combination therapy with ARB and calcium channel blockers is more effective in reducing the incidence of…
- Trial name
- NCT00134160
- Testing
- Olmesartan medoxomil, Calcium channel blockers (amlodipine, azelnidipine)
- Where
- 2 sites in Japan
- Volunteers
- 1,000 people
- Sponsor
- OSCAR Study
Venous Thromboembolism
Retrospective Study to Review Patients at Risk for VTE at Hospital Discharge
An investigator initiated study exploring VTE prophylaxis at the time of hospital discharge.
- Trial name
- NCT00604370
- Volunteers
- 2,500 people
- Sponsor
- Brigham and Women's Hospital
Atherosclerosis
Accelerated Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging
The goal of this study is to assess a slimy substance that settles/deposits along blood vessel wall. This slimy substance is called plaque. Plaque could be made up of fat, calcium or both. Plaque deposition narrows the vessels.
- Trial name
- NCT02114697
- Testing
- Statin therapy, Lifestyle modification
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
Acute Ischemic Stroke
Study to Evaluate The Safety and Efficacy of Balovaptan in Participants With Acute Ischemic Stroke at a High Risk of Developing Malignant Brain Edema
This study is designed to evaluate the safety, efficacy, and pharmacokinetics of balovaptan compared with placebo in participants with acute ischemic stroke (AIS) at risk of developing Malignant Cerebral Edema (MCE)
- Trial name
- NCT05399550
- Testing
- Balovaptan
- Where
- United States
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2, Cardiovascular Disease
High Potency Statins and the Risk of Diabetes
Statins are a class of cholesterol lowering medications that are prescribed for the prevention and treatment of cardiovascular disease.
- Trial name
- Statins-DM (NCT02518503)
- Testing
- Rosuvastatin (≥10 mg), Atorvastatin (≥20 mg), Simvastatin (≥40 mg)
- Volunteers
- 136,966 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Non-Hodgkin's Lymphoma, Acute Leukemia in Remission
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
The purpose of this study is to find out if a combination of drugs (these are called: cyclophosphamide, sirolimus, and mycophenolate mofetil) will protect participants better against graft vs.
- Conditions
- Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia, Primary Myelofibrosis
- Trial name
- NCT03018223
- Testing
- Fludarabine, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Patients With Symptoms of Cardiac Arrhythmia at Risk for Atrial Fibrillation
THE GIRAFFE Study: Genomic Risk Markers for Atrial Fibrillation Following Extended Cardiac Rhythm Monitoring
Our primary hypothesis is that a risk score comprised of approximately 10 single nucleotide polymorphisms (SNPs) that are associated with atrial fibrillation at the Genome Wide Association Study (GWAS) level is associated with…
- Trial name
- GIRAFFE (NCT01970969)
- Where
- United States
- Volunteers
- 928 people
- Sponsor
- Scripps Translational Science Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.